Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb's Complex Generics Remarks Could Signal (Some) Increased Flexibility

Executive Summary

US FDA commissioner spoke to agency scientists and researchers at Generic Drug Science Day, where he discussed future plans to facilitate complex generic development.

Advertisement

Related Content

Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Opioid, NME, And Generic Drugs Changes Plotted In US FDA's 2018 Policy Roadmap
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit

Topics

Advertisement
UsernamePublicRestriction

Register

PS122042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel